Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Genentech executes another round of layoffs, with 3 VPs axed
(1h)
AI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data finds
(2h)
Novo reports data breach, tells clinical trial patients to 'remain vigilant'
(2h)
Beyond Rigid Platforms: Adaptive Adenoviral Platform De-Risks Development to GMP
(4h)
Roche nabs EU approval on label expansions for companion dx platform
(6h)
BioPharma Dive
Summit pulls $500M share sale a day after announcing it
(3h)
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
(4h)
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
(5h)
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
(8h)
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
(1d)
Endpoints News
Inside Makary’s ouster; Another win for Lilly’s triple-G; and more
(3w)
FDA clears Gilead's hepatitis D drug, four years after prior rejection
(3w)
GOP lawmaker asks Trump administration to curb China biotech deals
(3w)
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
(3w)
How Utah’s AI prescribing experiment is going so far
(3w)
BioSpace
Genentech R&D layoffs hit top exec who’s been with the biotech nearly 30 years
(5h)
Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs
(5h)
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial
(6h)
SonoThera bags $125M series B to advance safer gene therapies
(8h)
Novartis tightens bond with Orionis in up to $1.4B molecular glue deal
(8h)
STAT News
AMA and lawmakers push back on AI care denials
(4m)
Nonprofit buys experimental cancer drug to maintain patient access
(56m)
Study highlights influence of socioeconomic status on children’s brain development
(1h)
Abridge inks deals with Nvidia and Lilly
(2h)
A suspicious denial pattern in Medicare Advantage
(4h)
BioPharma Trend
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2w)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(1mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(2mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(2mo)
Drug Channels
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)
(9h)
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update (rerun)
(1d)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments (rerun)
(2d)
The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies (rerun)
(3d)
Pharmacy Copay Misuse: The Multi-Billion Dollar Issue Hiding In Plain Sight
(6d)
European Biotechnology Magazine
Novartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bn
(7h)
Heidelberg-based Veraxa ventures onto Nasdaq in turbulent market environment
(11h)
Scenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’s
(11h)
Sanofi’s $11.6bn Bioverativ purchase looks hit-and miss after phase 3 rare diseases drug runs into trouble
(1d)
Circio completes NOK300m financing to fund circular RNA platform development
(1d)
Drug Hunter
Locking the Sec61 Gate to Corral Disease
(4h)
linerixibat
(1d)
NVP-INE963
(2d)
sonrotoclax (BGB-11417)
(3d)
Module 4 Quiz
(3d)
Labiotech.EU
How Daiichi Sankyo aims to become a top five oncology player by 2035
(1d)
Beyond amyloid and dopamine: emerging technologies reshaping neurology
(1d)
Pharma in Spain: why global investors and innovators are moving in
(2d)
Top biotech deals in May 2026
(3d)
Eight oncology deals in 2026 spotlight where industry leaders are betting big
(6d)
Bio IT World
Navigating the Perilous Journey from Lab to Market
(1d)
As AI Reshapes Drug Discovery the Lab Remains the Bottleneck
(2d)
Federation Plus Fine Tuning: The Push for Federated Learning Models Continues
(1w)
Trends from the Trenches: AI-Ready Life Sciences Data
(1w)
A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs
(1w)
GEN News
Potential Cocaine Addiction Targets Identified Through Genetic Mapping in Rats
(1h)
New mRNA Delivery Platform Restores Muscle Function in DMD Models
(2h)
Fighting Antimicrobial Resistance with Biomaterials and Phages
(4h)
GSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC Treatments
(22h)
Origins of First Eukaryotes Linked to Contributions from Multiple Bacteria and Giant Viruses
(23h)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(2mo)
Understanding High-Risk Essential Thrombocythemia
(2mo)
Son’s Decision to Donate Gave His Father a Second Chance
(2mo)
Functional Precision Medicine Advances Brain Tumor Care
(2mo)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(2mo)
Contract Pharma
Harbour BioMed Adds Luisa Salter-Cid as Scientific Advisor
(29m)
PharmaEssentia Acquires Forus Therapeutics, Expanding Footprint in Canada
(1h)
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B
(5h)
ACG Packaging Materials Achieves ISO Certification for Croatia Facility
(5h)
Cytovance Biologics Adds Cell Line Development Services
(6h)
Pharma Times
NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
(9h)
Anocca doses first patients with precision TCR‑T therapy
(10h)
Connecta launches phase 2a trial of neuroplasticity modulator
(1d)
Aquipta recommended by NICE for acute migraine treatment
(1d)
Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
(2d)
Medcity News
Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease
(1h)
From Copilots to Clinical Judgment: The Next Phase of AI in Digital Behavioral Health
(5h)
AI Is Scaling Healthcare Costs Because the System Was Built That Way
(5h)
What Healthcare Leaders Get Wrong About EHR Switching
(5h)
The Identity Gap Undermining Value-Based Care
(7h)
Chemical & Engineering News
Toxic chemicals accumulate in vapes as their juice runs low
(1h)
A new, ultrabright laser powers a cryo-EM advance 15 years in the making
(1h)
Coenzyme works as a molecular brake for labor
(1h)
Freepoint Eco-Systems shuts down controversial plastics pyrolysis plant
(2h)
Evonik plans revamp to make R&D go faster
(3h)
The Pharma Letter
City Therapeutics
(1h)
Wegovy pill becomes first and only daily GLP-1 weight loss tablet approved in UK
(4h)
Takeda’s zasocitinib outperforms deucravacitinib in PsO
(4h)
From raising awareness to developing treatments, Alexion is fighting HPP battle on many fronts
(4h)
Richter and Hetero collaborate on Ozempic generic
(5h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(2mo)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(2mo)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(2mo)
Treating Triple Negative Breast Cancer in the Frontline Setting
(2mo)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(2mo)
MedWatch
US employers are considering dropping coverage for GLP-1 medications in 2027
(7h)
EU court urged to prioritize vaccine contract transparency over corporate interests
(8h)
EU’s new medicines act strikes a difficult balance
(8h)
Pfizer to adjust planned investments in Germany after new pricing policy
(9h)
Johnson & Johnson acquires Firefly Bio for USD 1 billion
(10h)
In The Pipeline
Hydroxyl Radicals In Water Droplets? Doesn't Look Like It.
(2h)
A New Antibiotic Idea From An Old Source
(1d)
Insights Into Idiopathic Pulmonary Fibrosis
(2d)
Unusual Toxicity With a Protein Degrader Molecule
(3d)
The Causes of Long Covid
(7d)
Pharmaphorum
UK approves Novo Nordisk's Wegovy pill
(2h)
Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest
(3h)
J&J adds rare disease wAIHA to Imaavy's potential uses
(6h)
Novartis gets win for another Avidity muscular dystrophy AOC
(7h)
Basketball great Shaq fronts Lilly sleep apnoea campaign
(8h)
Drug Discovery Weekly
DaltonTx launches AI drug discovery platform
(5h)
Webinar – The orchestrated lab: Moving beyond siloed automation
(9h)
Bead BioPharma emerges from stealth with novel drug platform
(9h)
AMR Bio confirms contribution to US National Action Plan
(10h)
Webinar: Overcome critical bottlenecks in fragment-based drug discovery
(11h)
HIT Consultant
Why Validation is Becoming the Proving Ground for AI in Life Sciences
(4h)
Med-Metrix Acquires CanAide to Automate Patient Access
(5h)
Surgical AI Startup Uncovr Emerges from Stealth with $7M Seed Funding
(7h)
Scispot Secures $8M to Expand AI-Native Operating Layer for Modern Labs
(2d)
Hybrid Care 2.0: How AI-Powered Telehealth and Predictive Analytics Are Redefining Medicine
(2d)
Insights: Pink Sheet
UK’s HRA Maps Path To Regulatory Clarity For AI-Enabled Trials
(4h)
US-Approved Drugs Otarmeni, Idvynso And Unloxcyt Filed In EU
(6h)
Asundexian, Venglustat And Japanese Encephalitis Vaccine Among Latest EU Filings
(6h)
Japan Grapples With Off-Label Mounjaro Trade For Weight Loss
(11h)
Policy Priorities For An Innovative Korean Ecosystem
(15h)
BioXconomy
New study reveals $35 as tipping point for prescription abandonment
(1h)
Japan urged to regulate generative AI in clinical trials
(2h)
Dodging the cytokine storm: Delivering ASOs without adverse effects
(5h)
Lilly adds to neuroscience portfolio with $1bn AlzeCure Alzheimer's pact
(6h)
Sofinnova and AWS deliver AI to portfolio companies’ door
(7h)
BioCentury
Pinnacle: Designing oral peptides to close the gap with injectable biologics
(20h)
Moving faster at the academia-industry interface — a BioCentury podcast
(20h)
LRRK2 inhibitor failure pushes Parkinson’s field toward genetic enrichment
(20h)
Where Parabilis’ massive IPO ranks among biotech debuts on NASDAQ
(21h)
The race for a vaccine against rare Ebola virus
(1d)
SCRIP
ADA 2026: Roche Still Looking For Ways To Stand Out In Obesity
(3h)
Executives On The Move: Four CEOs And Five CFOs Among This Week’s Changes
(5h)
US Drug Shortages Ease But Discontinuations Surge, Asia Supply Chain Risks Run Deep
(6h)
Positive Del-Brax Biomarker Data Offers Early Support For Novartis’s Avidity Bet
(6h)
Orionis Back In Novartis’s Orbit With New Molecular Glue Deal
(6h)